News Focus
News Focus
Followers 232
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: KevGee59 post# 240085

Saturday, 01/11/2020 11:30:31 AM

Saturday, January 11, 2020 11:30:31 AM

Post# of 448089
Kev- Seriously? As I’ve stated a number of times I anticipate 10,449,172 will be OB’d in January update. This is a composition patent. Irregardless of getting in OB this patent is good until 2038 (I need confirmation on this). Also the 10/4 patent (my nickname for 10,449,172) qualifies for 5 year patent extension for R-I development if OB’d. Total possible lifecycle 2043....that’s 23 years of just Vascepa and doesn’t include MOCHIDA IP or AMR102/103 IP.

Lipitor does not out do Vascepa in IP.

BB

FDA rules and law here:
https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity#howlongpatentterm

Is 10/4 untimely? No. It is a composition patent based on R-I. Direct infringement if using the compound for Marine (arguable) and R-I (cold hard fact) prevents generic sale of Vascepa.

If you're not good at being yourself, then maybe that's being yourself!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News